<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365326">
  <stage>Registered</stage>
  <submitdate>15/11/2013</submitdate>
  <approvaldate>19/11/2013</approvaldate>
  <actrnumber>ACTRN12613001277730</actrnumber>
  <trial_identification>
    <studytitle>Oral L-tyrosin for reversing gray hair; a clinical trial</studytitle>
    <scientifictitle>The effect of supplementary oral L-tyrosin plus other essential elements (Dr Daniel capsule for gray hair) on reversing gray hair</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None.</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gray hair</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Normal skin development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Three groups of normal men with gray hair (total=15) will receive daily oral L-tyrosin 500 mg or 3000 mg daily plus other essential elements including 50 mg (in cases on 500 mg L-tyrosin) or 300 mg (in cases on 3000 mg L-tyrosin) 5-hydroxytriptophan (5-HTP) and 500 mg cysteine (Dr Daniel capsule for gray hair) in the intervention groups; or oral placebo (glucose) in the control group for 6 consecutive months.
Diet will be similar during the study period in all three groups.
Adherence interventions will include monthly instruction in forms of oral and written material.
Adherence to taking medication will be monitored by drug capsule return monthly.
</interventions>
    <comparator>Patients in the control group will receive oral placebo (capsules identical to those with medication in the intervention groups, containing only glucose) once daily for 6 consecutive months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of gray hairs on the frontal, parietal, temporal and occipital regions on both sides, separately.
For this purpose, the participants will wear a specially designed yarn hat with holes (10 cm in diameter) on each region of the skull on both sides. An examiner will count gray hairs in each hole separately under direct light and magnification. </outcome>
      <timepoint>baseline, month 3, month 6, month 9.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Possible complications of L-tyrosine plus 5-HTP such as problems in appetite, sleep, sexual behavior, temperature and pain sensation, nausea, fatigue, headaches, heartburn, joint pain, mood changes, irritability and changes in heart rate by asking from patients.</outcome>
      <timepoint>During the study period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Normal men with gray hair.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Secondary gray hair, malnutrition, taking other medications/supplements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers.</concealment>
    <sequence>Simple randomisation using a randomisation table created by computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Repeated measures analysis.
Due to lack of previous similar study, the investigators decided to conduct it as a pilot study on 5 cases in each group.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>31/12/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>East Azerbaijan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Daniel F Fouladi</primarysponsorname>
    <primarysponsoraddress>Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh Building, Daneshgah St., Tabriz-Iran. Post Code: 51656-65811.</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tabriz University of Medical Sciences, Drug Applied Research Center</fundingname>
      <fundingaddress>Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh Building, Daneshgah St., Tabriz-Iran. Post Code: 51656-65811.</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Previously it has been found that a tyrosine kinase inhibitor can reverse gray hairs of receivers. Tyrosine is an important precursor of melanin, an agent that directly produces hair color. This study for the first time investigates the effect of oral L-tyrosin (plus other important factors in the metabolism of melanin) in possible reversing of gray hair.   </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tabriz University of Medical Sciences</ethicname>
      <ethicaddress>Tabriz University of Medical Sciences, Daneshgah Square, Daneshgah Street, Tabriz-Iran, Postal Code:51664.</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>15/12/2013</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Daniel F Fouladi</name>
      <address>Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh Building, Daneshgah St., Tabriz-Iran. Post Code: 51656-65811.</address>
      <phone>+989144122542 </phone>
      <fax />
      <email>medicorelax@yahoo.com </email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Daniel F Fouladi</name>
      <address>Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh Building, Daneshgah St., Tabriz-Iran. Post Code: 51656-65811.</address>
      <phone>+989144122542 </phone>
      <fax />
      <email>medicorelax@yahoo.com </email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Daniel F Fouladi</name>
      <address>Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh Building, Daneshgah St., Tabriz-Iran. Post Code: 51656-65811.</address>
      <phone>+989144122542 </phone>
      <fax />
      <email>medicorelax@yahoo.com </email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Daniel F Fouladi</name>
      <address>Drug Applied Research Center, Tabriz University of Medical Sciences, Pashmineh Building, Daneshgah St., Tabriz-Iran. Post Code: 51656-65811.</address>
      <phone>+989144122542 </phone>
      <fax />
      <email>medicorelax@yahoo.com </email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>